Health
Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus – News-Medical.Net
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
General20 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General23 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News22 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business20 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher